HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer's Actron OTC ketoprofen set to launch "within weeks".

This article was originally published in The Tan Sheet

Executive Summary

BAYER'S ACTRON OTC KETOPROFEN LAUNCH COMING "WITHIN WEEKS," the company said, following FDA's Oct. 6 approval of the 12.5 mg strength of the NSAID for OTC analgesic indications. Calling Actron "extremely important" to the company and promising a "formidable launch," Bayer said it intends to support its new Rx-to-OTC switch with major promotional campaigns directed at consumers, physicians and pharmacists.

You may also be interested in...



Second Time Lucky? Sumatriptan One Of Three Switches On The Cards In Germany

A second attempt at switching sumatriptan for migraines, as well as switch applications for non-steroidal anti-inflammatories ketoprofen and liquid ibuprofen, are all on the agenda at Germany's next Expert Committee for Prescription meeting in June. 

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

RS145148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel